A compound of formula (I) or pharmaceutically acceptable salts or hydrates thereof:
A compound of formula (I) or pharmaceutically acceptable salts or hydrates thereof:
wherein R is chosen from phenyl, a 6-membered heteroaryl group, cyclohexyl, a 5-membered heteroaryl group; a bicyclo [3.1.0] hexanyl group; a C2-C5 alkynyl group; and a cubanyl group; wherein R1 and R2, independently, are chosen from H; C1-C6 alkyl (optionally substituted with one or more halogens); C1-C6 alkyl-S(O)n—; CO2H (or C1-C6 alkyl esters thereof or C1-C6 alkyl amides thereof); halogen; C1-C6 alkoxy; CN; NO2; and NR7R8; wherein R7 and R8, independently, each represent H, C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxycarbonyl, arylsulphonyl, heteroarylsulphonyl, heterocyclosulphonyl, arylcarbonyl, heteroarylcarbonyl, heterocyclocarbonyl, or C1-C6 alkylsulphonyl, or R7, R8 and the nitrogen to which they are attached form a 5 or 6 membered heterocyclic ring (such as morpholine or piperidine); and wherein n represents 0-2.
C07D 473/06 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07C 273/18 - Preparation of urea or its derivatives, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
C07D 239/545 - Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
2.
COMPOUNDS FOR THE PREVENTION AND/ OR TREATMENT OF SENESCENT CELL-RELATED PATHOLOGIES AND DISEASES
The invention concerns a compound of formula (I) or pharmaceutically acceptable salts or hydrates thereof: (I) wherein R represents a 6-membered aryl or heteroaryl group or a 5-membered heteroaryl group, optionally substituted with at least one halogen atom, for use as a medicament. The invention also concerns a pharmaceutical composition comprising, as active ingredient, at least one compound of formula (I), as above, or pharmaceutically acceptable salts or hydrates thereof, and at least one pharmaceutically acceptable excipient, and the pharmaceutical composition for use as a medicament. The invention also concerns such compound or pharmaceutical composition for use as HSP90 inhibitor, in selectively killing senescent cells, in delaying ageing in a subject and in the treatment and/ or prevention of a senescence -associated disease or disorder. The invention also concerns a method for preparing such compound. The invention also concerns the cosmetic use of the compounds of formula (I) or cosmetically acceptable salts or hydrates thereof, and of a cosmetic composition that comprises at least one such compound.
C07C 307/00 - Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
2516n21616162781-6161-616788 and the nitrogen to which they are attached form a 5 or • 6 membered heterocyclic ring (such as morpholine or piperidine); and • - n represents 0-2; for use as a medicament, in particular as HSP90 inhibitor, in selectively killing senescent cells, in delaying ageing in a subject and in the treatment and/or prevention of a senescence-associated disease or disorder.
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 37/00 - Drugs for immunological or allergic disorders
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 473/04 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
C07D 473/06 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Universal device for continuous spinal anesthesia (100) comprising: an introducer needle (101) for subarachnoid anesthesia; a spinal needle (103) coaxial with the introducer needle (101) and equipped with a mandrel (104); a spinal catheter (105); and a bridge cannula (102) overlapping a terminal portion of said spinal needle (103) and having a length shorter than the length of the spinal needle (103), said bridge cannula (102) being able to facilitate the insertion of the spinal catheter (105) and to be inserted, together with the spinal needle (103) equipped with the mandrel (104) and by means of the introducer needle (101), into the ligaments of the spinal column of a patient until it reaches the subarachnoid space.
patents
